Could ditching heparin during heart valve repair cut bleeding risks?
NCT ID NCT01823393
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether performing balloon aortic valvuloplasty without the blood thinner heparin reduces serious bleeding and blood vessel complications. About 94 adults with severe, symptomatic aortic stenosis will be randomly assigned to receive either heparin or a placebo during the procedure. The study aims to see if avoiding heparin lowers complications without increasing the risk of stroke or other ischemic events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Heparin (unfractionated heparin) and placebo (NaCl)
- What this could lead to
- If skipping heparin works, it could make a common heart procedure safer by lowering bleeding and blood vessel damage risks.
- What could go wrong
- This is a small, single-center trial. Skipping heparin might increase the chance of blood clots or stroke during the procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC STENOSIS, NON-RHEUMATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montpellier University Hospital
Montpellier, 34295, France